Research and Markets: Novartis: Performance, Products, Pipeline & Potential - Oncology Continues to Lead the Way

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/5dffb7/novartis_performa) has announced the addition of the "Novartis: Performance - Products - Pipeline - Potential" company profile to their offering.

Snapshot Novartis - Oncology leads the way in 2010

The oncology division lead sales growth in 2010, and with oncology being a major focus for Novartis this trend is set to continue. Novartis has an extensive oncology pipeline, the largest of its therapeutic areas, with promising compounds such as panobinostat and midostaurin, which could prove to be future growth drivers.

We predict that Diovan and Glivec/Gleevec will continue to demonstrate substantial sales growth within the medium term. In addition, the launch and approval of a selection of products which include Exjade (deferasirox), Xolair (omalizumab), Exforge (valsartan+amlodipine) and Lucentis (ranibizumab), should offset the decline in sales of a number of Novartis' strategic products.

In the longer term, as a research-intensive company which has benefited from the Chiron acquisition, Novartis has a strong pharmaceutical pipeline with a total of 147 projects under development.

Forecast Sales of Major Products to 2017 But what's in the pipeline? For the full story on Novartis' challenges and opportunities order this important strategic analysis today

This new strategic report provides a detailed analysis of Novartis' competitive position and prospect for the futures. Using primary source information complemented by original 7-year product forecasts and competitive analysis, the report gives a complete and compelling oversight of the company, its products, pipeline and prospects.

Buyers of the web edition receive online access for one year via an easy-to-use interface with fast navigation and a full text search facility. All formats are the same price.

Some Key Topics Covered in this Report:

  • Executive Summary
  • Therapeutic Area Focus
  • Key Product Analysis And Forecasting
  • Cardiovascular And Metabolism
  • Oncology/Haematology
  • Neuroscience
  • Ophthalmics/Dermatology/Gastrointestinal/Urology
  • Infectious Diseases/Transplantation/Immunology
  • Arthritis/Bone
  • Respiratory
  • Operational Data

Over 70 Companies Mentioned in this Report, Some Include:

  • Ablynx
  • Alfacell Corporation
  • Allergan
  • Alnylam Pharmaceuticals
  • AstraZeneca
  • Avanir Pharmaceuticals Corporation
  • Avalon Pharmaceuticals
  • Bausch & Lomb Inc
  • Broad Institute / Harvard University
  • Bayer Schering Pharma
  • Biovail Corporation
  • Celgene Corporation
  • Cell Genesys Inc
  • Cell Therapeutics Inc
  • Cerimon Pharmaceuticals Inc
  • Genentech
  • Gilead Sciences Inc
  • Human Genome Sciences (HGS)
  • Idenix Pharmaceuticals Inc
  • Idera Pharmaceuticals Inc
  • MicroDose Technologies Inc
  • Mitsubishi Tanabe Pharma Corporation
  • Molecular Insight Pharmaceuticals Inc (MIP)
  • MorphoSys AG
  • sanofi-aventis
  • Valley Forge Pharmaceuticals Inc
  • Vectura Group plc/Arakis Ltd
  • Vernalis plc
  • Xenon Pharmaceuticals Inc
  • XOMA Ltd

To view all companies mentioned and for more information, please visit http://www.researchandmarkets.com/research/5dffb7/novartis_performa

Source: Espicom Business Intelligence Ltd



CONTACT:

Research and Markets
Laura Wood, Senior Manager
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
[email protected]

KEYWORDS:   Europe  Switzerland

INDUSTRY KEYWORDS:   Health  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.